EN
SINOVAC Made Major Announcements Today
On June 4, 2024, Vice-President of Brazil and Minister for Development, Industry and Trade Geraldo Alckmin met with Mr. Yin Weidong, Chairman, President, and CEO of SINOVAC, in Beijing, China.
Vice-President of Brazil and Minister for Development, Industry and Trade Geraldo Alckmin (Right) meet with
SINOVAC Chairman, President, and CEO Weidong Yin (Left)
SINOVAC, whose COVID-19 vaccines are the first to enter the Brazilian market during the pandemic, is a leading biopharmaceutical enterprise in China. Today, the company made major announcements of investment in Brazil as follows:
Firstly, SINOVAC plans to invest $100 million in Brazil starting in 2024, mainly for cell therapy and localized production of vaccines and monoclonal antibodies. Currently, SINOVAC is engaged in intensive discussions with potential partners.
Secondly, SINOVAC and Fiocruz jointly announced their intention to cooperate in vaccine research and development. In this way, both sides jointly strengthen their roles as the official representatives of Brazil and China, respectively, in the BRICS vaccine R&D center, established in 2022. This center aims to enhance the production capacity of participating countries and make access to vaccines more equitable. The institutions already signed the confidentiality document, which is the first step in establishing a partnership to search for solutions that expand access to vaccines and quickly combat pandemics and health crises. During the WHA77 in Geneva, BRICS health ministries reaffirmed their commitment to this important initiative for global health.
Vice-President of Brazil and Minister for Development, Industry and Trade Geraldo Alckmin meet with
Mr. Yin Weidong, Chairman, President, and CEO of SINOVAC
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is a China-based global biopharmaceutical company, with a mission of "supply vaccines to eliminate human diseases", the company specializes in the research, development, manufacturing and commercialization of vaccines and related biological products that protect against human infectious diseases.
The company's diversified portfolio includes vaccines for influenza, viral hepatitis, varicella, Hand-Foot-Mouth disease (HFMD), poliomyelitis, pneumococcal disease, etc., of which 3 vaccines have been prequalified by WHO, including inactivated hepatitis A vaccine Healive®, Sabin-strain inactivated polio vaccine (sIPV), and varicella vaccine.
SINOVAC has a leading edge in developing vaccines to combat infectious disease outbreaks and was among the first to initiate R&D during major public health emergencies, including SARS, H5N1, H1N1, and COVID-19. The company developed the world's first inactivated SARS vaccine (Phase I completed), China's first H5N1 influenza vaccine (Paneflu®), the world's first H1N1 influenza vaccine (Panflu.1®), and CoronaVac®, the most widely used inactivated COVID-19 vaccine globally.
Beyond its marketed portfolio, the company is advancing a robust pipeline that includes combination vaccines,recombinant protein vaccines and next-generation platforms such as mRNA technologies and antibodies.
With a long-standing commitment to innovation and global health, SINOVAC is expanding its global footprint by strengthening partnerships with research institutions, international organizations, and local partners. Through broader market presence, technological cooperation, and localized production, the company aims to accelerate vaccine development and supply, enhance regional access to high-quality products, and better address unmet medical needs while improving preparedness for future pandemics.
For more information, please see the Company’s website at www.sinovac.com.